Pediatric Inflammatory Bowel Disease
- PMID: 11096601
- DOI: 10.1007/s11938-000-0055-2
Pediatric Inflammatory Bowel Disease
Abstract
The combination of an unprecedented number of new therapeutic options (Fig. 1), along with new insights in how to optimize currently available therapies and advances in our understanding of disease pathogenesis, present many exciting new aspects to the management of patients with inflammatory bowel disease (IBD). Clinical management paradigms must evolve in parallel to keep pace with these advances. Traditional pediatric IBD regimens have underutilized combination therapies (Fig. 2) and immunomodulatory agents. Increased appreciation for steroid side effects is leading to a shift away from their inclusion in maintenance regimens. Immunomodulators are being introduced earlier in the course of disease for maintenance of remission and growth promotion. Recognition that the sole signs of active disease in children and adolescents may be growth and maturational delay, despite a relative lack of gastrointestinal symptoms, should prompt earlier, more aggressive interventions. When more potent, rapidly acting interventions such as infliximab, cyclosporine (CSA), or tacrolimus are considered, they should generally be co-administered with agents such as 6-mercaptopurine (6-MP) or azathioprine (AZA) for longer-term disease suppression.
Similar articles
-
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
-
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294385 Free PMC article.
-
Medical therapy of inflammatory bowel disease for the 21st century.Eur J Surg Suppl. 1998;(582):90-8. doi: 10.1080/11024159850191517. Eur J Surg Suppl. 1998. PMID: 10029372 Review.
-
Inflammatory bowel disease: current therapeutic options.Digestion. 2006;73 Suppl 1:67-76. doi: 10.1159/000089781. Epub 2006 Feb 8. Digestion. 2006. PMID: 16498254 Review.
-
Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.World J Gastroenterol. 2019 Mar 7;25(9):1142-1157. doi: 10.3748/wjg.v25.i9.1142. World J Gastroenterol. 2019. PMID: 30863001 Free PMC article.
References
LinkOut - more resources
Full Text Sources